Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 80 and over Aged. Found 154 abstracts

no pagination
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys. 2016 Mar;94(3):554-60.   PMCID: 4876948
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386-91.   PMCID: 4447525
Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15;21(16):3610-8.   PMCID: 4790106
Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzburg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 2015 Sep;33(9):388e19-388e25.   PMCID: 4289664
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 05;373(19):1803-13.
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 08;125(2):236-41.   PMCID: PMC4287635
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Revenig LM, Canter DJ, Henderson MA, Ogan K, Kooby DA, Maithel SK, Liu Y, Kim S, Master VA. Preoperative quantification of perceptions of surgical frailty. J Surg Res. 2015 Feb;193(2):583-9.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46.
Wang EH, Yu JB, Gross CP, Smaldone MC, Shah ND, Trinh QD, Nguyen PL, Sun M, Han LC, Kim SP. Variation in pelvic lymph node dissection among patients undergoing radical prostatectomy by hospital characteristics and surgical approach: results from the National Cancer Database. J Urol. 2015 Mar;193(3):820-5.
Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Pract Radiat Oncol. 2015 Sep;5(5):e457-63.   PMCID: 4814166
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2014 Aug 21;124(8):1259-65.   PMCID: Pmc4141515
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44.   PMCID: Pmc4229637
Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20;32(12):1210-7.   PMCID: Pmc3986384
Dyer MA, Arvold ND, Chen YH, Pinnell NE, Mitin T, Lee EQ, Hodi FS, Ibrahim N, Weiss SE, Kelly PJ, Floyd SR, Mahadevan A, Alexander BM. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol. 2014 Jun;9:143.   PMCID: 4132230
Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, LeBlang SD, Roberts A, Choi J, Larner JM, Napoli A, Turkevich VG, Inbar Y, Tempany CM, Pfeffer RM. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J Natl Cancer Inst. 2014 May;106(5).   PMCID: 4112926
Johnson ME, Zhu F, Li T, Wu H, Galloway TJ, Farma JM, Perlis CS, Turaka A. Absolute lymphocyte count: a potential prognostic factor for Merkel cell carcinoma. J Am Acad Dermatol. 2014 Jun;70(6):1028-35.   PMCID: No NIH funding
Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer. 2014 Mar 15;120(6):840-7.   PMCID: Pmc3951722
Longacre ML, Ross EA, Fang CY. Caregiving Choice and Emotional Stress Among Cancer Caregivers. Western Journal of Nursing Research. 2014 Jul;36(6):806-24.   PMCID: 4148462
Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer. 2014 Jul 15;120(14):2114-21.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 80 and over Aged

Middle Aged 80 and over Aged Aged Adult Male Female pathology drug therapy mortality therapeutic use adverse effects methods Prognosis Disease-Free Survival Young Adult analogs & derivatives Cohort Studies Neoplasm Staging genetics radiotherapy administration & dosage Kaplan-Meier Estimate Monoclonal Antibodies complications Neoplasms Retrospective Studies Antineoplastic Combined Chemotherapy Protocols Chemoradiotherapy Prostatic Neoplasms Antineoplastic Agents Follow-Up Studies therapy blood Prospective Studies immunology Proportional Hazards Models metabolism Pancreatic Neoplasms Factual Databases Taxoids Combined Modality Therapy B-Cell Lymphoma Local Neoplasm Recurrence Prostatectomy Skin Neoplasms Adenocarcinoma chemically induced Quality of Life epidemiology Neoplasm Invasiveness Survival Rate Survival Analysis Biological Tumor Markers Risk Assessment secondary Ovarian Neoplasms Multivariate Analysis Sirolimus surgery Adolescent Survival psychology Neoadjuvant Therapy Kidney Neoplasms United States Renal Cell Carcinoma Glioblastoma Genetic Markers ultrasonography quality of health care Psychological Stress Biological Markers skin neoplasm Outcomes Melanoma Educational Status Rb1 nursing Urothelial carcinoma Age Factors Frail Elderly Reproducibility of Results Toxicity Ovarian cancer Choice Behavior Genotype head and neck cancer caregiving Veliparib Cisplatin Rural Population Superoxide Dismutase Lymphocyte count High-Volume Hospitals DNA Repair IGF Type 1 Receptor Fallopian Tube Neoplasms lymph node excision Dose Fractionation Weight Loss Merkel Cell Carcinoma Patient attitudes treatment outcome use Oxidative Stress Magnetic Resonance Imaging immune function Dacarbazine Gastrointestinal Diseases Renal cell carcinoma Piperidines dosage Cross-Sectional Studies Papillary renal cell carcinoma Karnofsky Performance Status Propionates Pain Registries High-Intensity Focused Ultrasound Ablation Randomized Controlled Trials as Topic Intensity-Modulated Radiotherapy etiology Medicare Utilization Review biosynthesis Treatment Outcome drug effects Prednisone Radiotherapy Dosage Merkel cell carcinoma Brain Neoplasms Neoplastic Gene Expression Regulation TOR Serine-Threonine Kinases Phase III Clinical Trials as Topic Double-Blind Method Genetic Polymorphism Urinary Bladder Neoplasms statistics & numerical data Atm Nutritional Status Combination Drug Therapy Deglutition Disorders baseline weight loss Quinazolines Sulfones Fancc Fluorouracil brachytherapy Neutropenia BRCA2 Genes
Last updated on Tuesday, September 06, 2016